No Cover Image

Journal article 153 views 26 downloads

Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK

Roxanne Cooksey Orcid Logo, Muhammad Azizur Rahman, Jonathan Kennedy, Sinead Brophy Orcid Logo, Ernest Choy

Rheumatology Advances in Practice, Volume: 5, Issue: 2, Start page: rkab042

Swansea University Authors: Roxanne Cooksey Orcid Logo, Jonathan Kennedy, Sinead Brophy Orcid Logo

  • 58661.pdf

    PDF | Version of Record

    Copyright: The Author(s) 2021.This is an Open Access article distributed under the terms of the Creative Commons Attribution License

    Download (252.72KB)

Check full text

DOI (Published version): 10.1093/rap/rkab042

Abstract

ObjectivesPsA and AS are chronic diseases associated with significant morbidities. National and international management guidelines include treatment with biologic therapies to improve outcomes and quality of life. There are limited real-world data on the patients’ journey from symptom onset to diag...

Full description

Published in: Rheumatology Advances in Practice
ISSN: 2514-1775 2514-1775
Published: Oxford University Press (OUP) 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa58661
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: ObjectivesPsA and AS are chronic diseases associated with significant morbidities. National and international management guidelines include treatment with biologic therapies to improve outcomes and quality of life. There are limited real-world data on the patients’ journey from symptom onset to diagnosis and treatment in the UK. We use real-life, linked health data to explore patient pathways and the impact of biologics on patient outcomes.MethodsData from the Secure Anonymised Information Linkage databank in Wales were used to assess diagnosis and treatment of patients ≥18 years of age with at least one International Classification of Diseases, Tenth Revision code present for PsA/AS in rheumatology clinic data and at least one Read code present in primary care records. We investigated the use of biologics while exploring demographics, comorbidities and surgical procedures of 641 AS patients and 1312 PsA patients.ResultsAS patients were significantly younger at diagnosis and were predominantly male. The average time from presenting symptoms to diagnosis of AS and PsA was 7.9 (S.D. 5.5) and 9.3 (S.D. 5.5) years, respectively. The proportion of patients receiving biologic treatment was significantly higher in AS (46%) compared with PsA patients (28.8%); of these, 23.1% of AS and 22.2% of PsA patients stopped/switched a biologic. There was a significant reduction in primary care involvement, sick notes and disability living allowance for both AS and PsA patients following biologic initiation.ConclusionThis real-world descriptive study confirms that patients treated with biologics have reduced disability and time off work despite being initiated ∼13 years after the first symptoms and 6 years after diagnosis.
Keywords: psoriatic arthritis, ankylosing spondylitis, biologics, outcomes, treatment pathways, electronic health records
College: Swansea University Medical School
Funders: Novartis Pharmaceuticals (grant 513540 to E.C.)
Issue: 2
Start Page: rkab042